EKF Diagnostics Holdings plc (AIM:EKF)

Market Cap	118.39M +29.1%
Revenue (ttm)	51.56M +2.7%
Net Income	2.12M -66.0%
EPS	0.00 -65.8%
Shares Out	430.50M
PE Ratio	58.52
Forward PE	16.76
Dividend	n/a
Ex-Dividend Date	n/a

Volume	130,926
Average Volume	231,044
Open	26.60
Previous Close	28.00
Day's Range	26.50 - 27.90
52-Week Range	21.80 - 32.00
Beta	0.53
RSI	60.77
Earnings Date	Jun 16, 2026

About EKF Diagnostics Holdings

EKF Diagnostics Holdings plc engages in the design, development, manufacture, and sale of diagnostic instruments, reagents, and other ancillary products in the Americas, Europe, the Middle East, Asia, Africa, and internationally. The company offers DiaSpect Tm hand-held hemoglobin analyzer; Hemo Control, a hemoglobin and hematocrit analyzer; and HemataStat II, a microhematocrit centrifuge that provides a quantitative hematocrit reading for six blood samples. It also provides glucose and lactate analyzers, such as Biosen C-Line GP+ and C-Line Cl...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1990
• Employees: 297
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: EKF

Financial Performance

In 2025, EKF Diagnostics Holdings's revenue was 51.56 million, an increase of 2.73% compared to the previous year's 50.19 million. Earnings were 2.12 million, a decrease of -66.00%.